Entry Point Capital, LLC Blueprint Medicines Corp Transaction History
Entry Point Capital, LLC
- $171 Million
- Q3 2024
A detailed history of Entry Point Capital, LLC transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Entry Point Capital, LLC holds 4,287 shares of BPMC stock, worth $403,621. This represents 0.23% of its overall portfolio holdings.
Number of Shares
4,287
Previous 1,289
232.58%
Holding current value
$403,621
Previous $139 Million
99.71%
% of portfolio
0.23%
Previous 0.2%
Shares
2 transactions
Others Institutions Holding BPMC
# of Institutions
352Shares Held
60.3MCall Options Held
2.25MPut Options Held
1.18M-
Vanguard Group Inc Valley Forge, PA6.68MShares$629 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.65MShares$626 Million0.02% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.39MShares$507 Million0.06% of portfolio
-
Wellington Management Group LLP Boston, MA3.96MShares$373 Million0.07% of portfolio
-
State Street Corp Boston, MA2.77MShares$260 Million0.01% of portfolio
About Blueprint Medicines Corp
- Ticker BPMC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,719,600
- Market Cap $5.62B
- Description
- Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...